☰

Cellex Cell Professionals GmbH

Scaling cell therapy manufacturing across data, OT and ESG

Industry
Cell and Gene Therapy CDMO
Headquarters
Cologne, Germany
Public information as of
February 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Cellex Cell Professionals GmbH's published strategy and is not endorsed by, or produced in cooperation with, Cellex Cell Professionals GmbH. Company website

Strategic priorities

Cellex Cell Professionals is a Cologne-based contract development and manufacturing organisation founded in 2001, with a workforce of over 380 specialists and over 2,500 sqm of GMP-certified manufacturing area, including 43% Grade B cleanroom across 37 individual workstations. The company controls the cell-therapy value chain from apheresis (Cellex Medical Services) through GMP manufacturing, cryopreservation and global GDP-compliant logistics (CMT).

Strategic priorities in 2026 include commercial-scale CDMO buildout, the AvenCell joint venture with Blackstone Life Sciences and Intellia for universal CAR-T therapies, partnerships with Swarm Oncology and Gift of Life Biologics, and Scope 3 sustainability reporting under the VSME standard. The math now runs in three places at once: the cleanroom, the OT network, and the auditor's reading room.

Operationally, growth is constrained by the friction in three transitions: between paper batch records and electronic batch records, between isolated lab instruments and a single Golden Batch record, and between a cleanroom workstation and the cloud data layer that drives analytics. Each transition is technically well-understood; the question on the table is the sequence in which it is undertaken.

This analysis treats each transition as a piece of work in its own right, prioritised against the partnerships that already depend on the answer, and scored against Cellex's current maturity rather than against a generic CDMO benchmark.

Challenges we see

  • Operations Manufacturing

    Scaling media exchange and QC release across 37 workstations

    Cellex manages 37 individual workstations across 2,500 sqm of GMP-certified manufacturing area, with 43% of that footprint allocated to Grade B cleanroom. Media exchange, incubation and QC release are the gate stages that determine the throughput of any given campaign.

    Where the gate stages of a campaign are paced by the longest manual step rather than by the instrument cycle time, the result is a long tail of half-finished work that grows with partner volume. Pre-positioning media and reading release data in advance keeps the bottleneck at the slowest decision rather than at the slowest hand-off.

  • Digital Integration

    Integrating heterogeneous lab equipment into a single Golden Batch record

    The facility runs flow cytometers, bioreactors and supporting instruments from multiple vendors. DocuSign is established as the e-signature layer, but core manufacturing batch records are still produced on paper or assembled at the signature step rather than as native digital records.

    Where instrument output is reconciled by hand into the batch record, the cost of a single Golden Batch comparison is the cost of one full reconciliation cycle. Capturing each instrument's output at the source with a shared reading protocol lets the Golden Batch comparison become a routine query rather than a manual exercise.

  • Compliance Regulatory

    Securing legacy equipment as it is connected to cloud data access

    ISO 27001 has been adopted across the IT estate, with 98% of staff completing mandatory IT training. The next exposure is the OT layer: air-gapped legacy equipment being connected to the cloud for data access carries risk that passive firewalls were not designed to detect.

    Where the boundary between the IT estate and the OT estate moves from air gap to controlled bridge, the engineering of that bridge — protocol translation, segmentation, monitoring — becomes part of what is being protected. The 2026 IEC 62443 and NIS2 programmes underway across the European pharmaceutical sector give a working reference for that engineering.

  • Operations Operations

    Monitoring LN2 cryostorage continuously across the new warehouse

    The new materials warehouse at Mathias-Brüggen-Str. 128 (commissioned 2025) houses cryopreservation capacity that must hold temperature across tens of thousands of patient doses. Each batch represents a per-dose cost in the hundreds of thousands of euros and a per-patient promise that runs against the clock.

    Where cryostorage temperature is confirmed by periodic sample rather than by continuous reading, the time between a deviation and the corrective action is bounded by the sampling cadence. Bringing the LN2 temperature, door state and replenishment activity into a single continuous record collapses that window to the speed of the alarm itself.

  • Compliance Regulatory

    Proving CMC comparability with pivoted process data

    The FDA's 2026 announcement of flexible approaches to Chemistry, Manufacturing and Controls (CMC) puts the comparability case — what changed, what stayed equivalent — at the centre of the submission. Demonstrating comparability with pivoted process data is a recurring workstream, not a one-off deliverable.

    Where the comparability case is assembled each time from spreadsheet exports, the time to a reviewer-ready answer is set by the slowest manual step. Holding process data in a structure that lets a scientist pivot a parameter and re-prove comparability in the same day turns the submission timeline from a calendar question into an analytical one.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Unified workstation visibility

    Batch progress across 37 workstations is currently tracked in disparate systems or manual whiteboards, leaving the operations team without a single real-time view of where each campaign stands.

    A P&ID (Piping and Instrumentation Diagram)-based visualisation platform that mirrors the cleanroom physical layout in Grafana dashboards, integrates live sensor data and pulls QC analytical results into the same view, so the ops team sees one campaign rather than 37 separate ones.

  2. Non-invasive bioprocess monitoring

    Cell-therapy cultures include fragile cells sensitive to foam build-up, while invasive probes in bioreactor environments create contamination risk and sensor fouling.

    Computer-vision Watchdog systems using external cameras with Python-based image processing to detect foam levels and trigger antifoam dosing in real time, without breaching sterile bioreactor boundaries.

  3. High-availability R&D infrastructure

    The AvenCell joint venture with Blackstone Life Sciences and Intellia runs complex switchable CAR-T (Chimeric Antigen Receptor T-cell) platforms that require large data-processing capacity; isolated industrial PCs introduce single points of failure for experimental data collection.

    Migration of R&D lab data systems to a clustered Incus environment with N+1 redundancy, decoupling software from hardware so workloads can move between nodes during a failure without interrupting the experiment.

  4. ESG data automation

    Cellex is publishing its first VSME-standard sustainability report including Scope 3 supply-chain emissions in 2026, but calculating a carbon footprint across suppliers, logistics partners and cryopreservation operations is not feasible by hand.

    Industrial-data pipelines that automate environmental metrics capture from manufacturing equipment, apheresis suppliers, logistics partners and cryopreservation, producing an audit-trailed sustainability record on the required schedule.

  5. QC laboratory digital transformation

    Core manufacturing batch records may still be paper-reliant or digitised only at the signature step, creating ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring, and Available) integrity risk and a high administrative burden across the 100+ annual audits.

    Transition from paper-based SOPs (Standard Operating Procedures) to a Laboratory Execution System (LES) with interactive P&ID dashboards, eliminating the manual transcription step from instrument screen to Excel and replacing detective controls with preventive ones.

What we'd propose

  • Digital CDMO

    Digital manufacturing command centre

    A unified real-time visibility platform that turns 37 cleanroom workstations into an integrated command centre with P&ID-based visualisation, severity-categorised alarms and batch-progress overlays. Built for a CMO (Contract Manufacturing Organisation) audience that wants to see one campaign rather than 37 separate ones.

    • P&ID visual dashboard

      Cleanroom layout in Grafana

      Rebuilding the main operations dashboards to visually replicate the piping and instrumentation diagrams of all 37 workstations, so the operator navigates by physical location rather than by tag.

    • Smart alarm management

      Severity categorised, low fatigue

      Intelligent alerting logic that categorises notifications by severity and shows only critical deviations, removing the alert-fatigue layer that comes with naive thresholding.

    • Batch progress tracking

      Real-time status overlay

      A global CMO view showing batch status across all workstations with automated milestone tracking and deviation flags, so the operations team sees one campaign rather than 37 separate ones.

    • Operators navigate by physical location rather than by tag, reducing the time to answer at the screen.
    • Critical deviations are surfaced without the noise of low-severity notifications.
    • The CMO view becomes part of the daily ops conversation rather than a weekly report.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Computer vision for non-invasive foam management

    An AI-powered non-invasive monitoring solution that uses external cameras and machine-learning algorithms to detect foam in cell-therapy bioreactors and trigger antifoam dosing, without breaching sterile boundaries or fouling invasive probes.

    • External camera integration

      No contact, no contamination

      External cameras with Python-based OpenCV image processing detect foam levels in real time without breaching the sterile bioreactor boundary, removing the contamination and fouling risk of invasive probes.

    • Adaptive dosing control

      Right response per foam type

      PWM (Pulse-Width Modulation), vector and interval dosing modes cover the different foam profiles encountered in cell-therapy cultures, including slow-rising and flash-foam scenarios.

    • 24/7 autonomous monitoring

      Faster than human eyes

      An autonomous monitoring loop that detects foam events faster than human operators can, with the controller taking the closed-loop action rather than alerting a person.

    • Foam events are caught before they translate into sensor failure or batch loss.
    • Antifoam use is calibrated to the foam profile, sparing cell growth from chemical excess.
    • The Swarm Oncology partnership throughput targets become a question of instrument cadence rather than of shift coverage.

    We've done this before

    See how we do Digital Lab
  • Digital Lab

    High-availability R&D infrastructure migration

    A resilient containerised computing architecture that migrates R&D lab systems from isolated industrial PCs to clustered Incus environments, with N+1 redundancy and infrastructure-as-code templates that travel between facilities.

    • Incus cluster deployment

      Decoupled software and hardware

      LXC/LXD (Linux container/virtual machine technologies) containerisation decouples lab applications from the host hardware so workloads can move between nodes during a failure or scheduled maintenance.

    • N+1 redundancy design

      Zero-downtime data collection

      A clustered environment designed so that a hardware failure on any node does not halt experimental data collection, preserving the AvenCell JV (joint venture) experimental records without interruption.

    • Infrastructure as code

      Same template across sites

      Standardised deployment templates so the same environment definition runs at each facility, removing version drift between the Cologne GMP site and the R&D site.

    • AvenCell JV intellectual property and experimental data sit on infrastructure that survives a single-node failure.
    • Remote infrastructure management replaces physical presence on the laboratory floor.
    • Single points of failure in data collection are removed before the next regulatory milestone.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Industrial data platform for ESG and operations

    An integrated data pipeline that automates environmental metrics capture from manufacturing equipment, apheresis suppliers, logistics partners and cryopreservation, producing an audit-trailed sustainability record alongside a continuous Golden Batch record. Brings shop-floor to cloud without manual data entry.

    • Shop-floor data integration

      Metrics capture from equipment

      Connection of manufacturing equipment and facility systems to capture energy consumption, water usage and waste metrics continuously, replacing the 2024 baseline of DocuSign savings tallies with measured data.

    • Supply chain data aggregation

      Partner emissions, not estimates

      Pipelines that ingest environmental data from apheresis suppliers, logistics partners and cryopreservation operations so Scope 3 figures are observed rather than estimated.

    • VSME reporting engine

      Auditable sustainability record

      A reporting engine that generates compliant sustainability documentation under the VSME (Voluntary Sustainability Reporting Standard for SMEs) standard with automated data validation and audit trails, ready for the 2026 deadline.

    • The 2026 Scope 3 deadline is met by measured data rather than by retrospective estimate.
    • The sustainability record is anchored in the same shop-floor data layer that supports Golden Batch.
    • Annual figures shift from sampled tallies to continuous reading.

    We've done this before

    See how we do Enterprise AI
  • Agents

    AI agents for CMC and ISO 27001 documentation

    Narrow, reviewable agents that take the repetitive part of regulatory and quality documentation at Cellex: drafting CMC comparability sections from process data, pre-populating EMA/FDA submission templates, mapping an ISO 27001 or VSME standards change to every controlled document it touches, and assembling audit-prep dossiers for the 100+ annual audits. A named reviewer approves every output.

    • Drafting from source records

      First drafts from the data

      Generation of the first draft of a CMC comparability section, an EMA/FDA submission module or a VSME paragraph directly from the underlying process and operational records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Pre-review check of a submitted document against its EMA/FDA template and the site's own checklist, returning missing sections and inconsistent cross-references before the document reaches the human reviewer.

    • Change impact search across the document set

      Which documents a standards change touches

      When an EMA guideline, an FDA guidance, an ISO 27001 control, or the VSME standard is updated, retrieval of every controlled document that references it — ranked by how directly it is affected — so the scope of an update is known on day one.

    • Submission drafts arrive at review complete and consistent with the template.
    • The scope of a standards change is established by search rather than by recollection.
    • Reviewer capacity is spent on judgement rather than on assembly.

    We've done this before

    See how we do Agents

Where QB Systems fits

Alongside our services we build QB Systems, hardware and software for bioprocess control. QB Systems is a product brand of A4BEE Sp. z o.o.

Applications
Bioreactors

Software-defined control for a bioreactor — a new QB vessel, an upgrade to one you have, or a retrofit of the existing PLC.

Automated sampling

Automated sampling from 4–18 sources, aseptic-capable and up to 72 hours unattended. Works with any vendor's bioreactor.

Buffer & media preparation

Automated preparation of growth media and process buffers, so a recipe runs the same way every time without fixed infrastructure.

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Cellex Cell Professionals GmbH's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Data integration 35 → 85
Flow cytometers, bioreactors and supporting instruments write to vendor-specific outputs; DocuSign is established at the e-signature layer but core batch records are produced on paper or assembled at the signature step rather than as native digital records.
Process automation 40 → 90
Media exchange, incubation and QC release carry manual intervention at each gate stage; 37 workstations run on independent cycles rather than on a coordinated release cadence.
IT/OT convergence 30 → 80
ISO 27001 has been adopted across the IT estate with 98% staff training completion; the OT layer remains the open exposure as air-gapped legacy equipment is connected to the cloud for data access.
Analytics capability 25 → 75
Golden Batch comparisons are reconstructed from spreadsheet exports each time they are needed; there is no continuous Golden Batch overlay and scientists do not yet have a self-service analytics surface for CMC comparability pivots.
Cybersecurity posture 45 → 85
ISO 27001 controls are in place across the IT estate; the OT layer for connected legacy equipment still relies on passive firewalls rather than on the IEC 62443 segmentation that the 2026 programmes point to.
ESG data management 20 → 70
Current sustainability metrics are annual tallies such as the 2024 DocuSign savings figure; Scope 3 reporting from 2026 requires continuous data capture across suppliers, logistics and cryopreservation.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of February 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Cellex Cell Professionals GmbH, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].